Prosecution Insights
Last updated: October 26, 2026
Application No. 19/089,388

METHODS, DEVICES, AND SYSTEMS FOR MONITORING INTRAOCULAR PRESSURE

Non-Final OA §102§DOUBLEPATENT
Filed
Mar 25, 2025
Priority
May 15, 2020 — provisional 63/025,617 +1 more
Examiner
HENSON, DEVIN B
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Icahn School of Medicine At Mount Sinai
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
2y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
526 granted / 808 resolved
-4.9% vs TC avg
Strong +43% interview lift
Without
With
+43.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
30 currently pending
Career history
851
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
46.3%
+6.3% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 808 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice of Amendment In response to the amendment filed on 11/4/2025, cancelled claims 1-30 and new claim 31 are acknowledged. Claim 31 remains pending. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. No claim limitation has been interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 31 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Karyotakis et al. (“Manometric measurement of the outflow facility in the living human eye and its dependence on intraocular pressure”, Acta Ophthalmologica, 2015, Vol. 93, pp. e343-e348) (cited by Applicant). Regarding claim 31, Karyotakis et al. discloses a system for monitoring a fluid outflow behavior of an eye of a subject, comprising: an infusion line configured to be inserted into the eye of the subject (see p. e344, col. 1-col. 2 – “The anterior chamber of the eye was cannulated to a microstepping pump (infused volume:0.08 µl/step), and the IOP was recorded by a pressure transducer(SSCM3175GA Sensortechnics, Puchheim, Germany, accuracy of 0.13 mmHg and resolution of 0.05 mmHg). The eye, the micro stepping pump and the pressure transducer were connected through inextensible tubes (Vygon, Ecouen, France); a sensor communicatively coupled to the infusion line, wherein the sensor is configured to continuously detect an intraocular pressure of the eye over a time period (see p. e344, col. 1-col. 2 – “The anterior chamber of the eye was cannulated to a microstepping pump (infused volume:0.08 µl/step), and the IOP was recorded by a pressure transducer(SSCM3175GA Sensortechnics, Puchheim, Germany, accuracy of 0.13 mmHg and resolution of 0.05 mmHg). The eye, the micro stepping pump and the pressure transducer were connected through inextensible tubes (Vygon, Ecouen, France); and a processor communicatively coupled to the infusion line and the sensor, wherein the processor is configured to generate a representation of the fluid outflow behavior of the eye based on the intraocular pressure of the eye over the time period (see p. e344, col. 2 – “The system was con-trolled by a purposely developed computer interface, programmed in LabView (National Instruments Inc., Austin, TX, USA), for the monitoring of both the procedure and the data acquisition, equation 5 on p. e345, and p. e345, col. 3 – “In the present study, C was measured using a direct manometric method that incorporates measurement of the K coefficient and steady-state IOP. Based on this approach, C and R coefficients were measured in a wide range of IOPs and it was shown that the value of C(and R) strongly depend on IOP”). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 31 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,285,217 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because present claim 31 is fully anticipated by reference claim 1. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEVIN B HENSON whose telephone number is (571)270-5340. The examiner can normally be reached M-F 7 AM ET - 5 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert (Tse) Chen can be reached at (571) 272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEVIN B HENSON/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Mar 25, 2025
Application Filed
Oct 13, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12752086
SYSTEMS AND METHODS FOR THE CONTROL OF MULTIPLE DEGREES-OF-FREEDOM BENDING AND THE BENDING LENGTH OF A COAXIALLY ALIGNED ROBOTICALLY STEERABLE GUIDEWIRE
3y 11m to grant Granted Oct 06, 2026
Patent 12751619
INTRAOCULAR PRESSURE SENSING DEVICE AND METHOD USING SENSOR BASED ON HALF WHEATSTONE BRIDGE
3y 3m to grant Granted Oct 06, 2026
Patent 12740726
METHOD AND APPARATUS FOR NON-INVASIVE ESTIMATION OF GLYCATED HEMOGLOBIN OR BLOOD GLUCOSE BY USING MACHINE LEARNING
2y 8m to grant Granted Sep 22, 2026
Patent 12734334
MEDICAL DEVICES WITH DISTAL CONTROL
4y 11m to grant Granted Sep 15, 2026
Patent 12727784
WIRELESS NEUROMUSCULAR SENSING DEVICE
7y 11m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+43.4%)
3y 8m (~2y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 808 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month